Bristol-Myers hepatitis C drug gets approval in Japan
July 7 (Reuters) - Bristol-Myers Squibb and Co said its combination drug for the treatment of hepatitis C was approved in Japan.
The treatment, which comprises Daklinza and Sunvepra drugs, is meant for patients who are intolerant or have failed to respond to standard medication. (Reporting By Penumudi Amrutha in Bangalore; Editing by Don Sebastian)
- Sierra Leone declares emergency as Ebola death toll hits 729 |
- Israel, Palestinian militant groups begin 3-day Gaza truce |
- Disappointment, uncertainty after India blocks WTO trade deal
- S&P500 index posts worst fall since April; indexes down for July
- Tesla expects to boost 2015 output to more than 60,000